Summary of the period January–March 2024
- Net turnover was
SEK 257,677 (120,421)
- Cash flow from operating activities was
SEK -5,908,058 (-8,479,928)
- Profit/loss after financial items was
SEK -6,019,201 (-7,113,134)
- Profit/loss after tax was
SEK -6,019,201 (-7,113,134)
- Earnings per share were
SEK -0.02 (-0.03)
Breakthrough in several markets and strengthened cash flow via an issue
During the first quarter of the year, much of our focus has been on introducing Ozilia Migraine in the industry and investor circles surrounding Life Science. During several investor congresses, we have connected with interesting contacts who see the potential in Ozilia.
We find another highlight during the first months of the year in
- First migraine patients treated in
Germany
- Strong interest at several investing congresses
- New case report on Ozilia published: “Effective for both pain relief and reduced frequency of migraine attacks”
- Patents approved in
Europe andUSA
- Cash strengthened by approximately
SEK 23 million before costs after the rights issue. Additional proceeds may come from warrant series T08
First migraine patients treated in
At the beginning of January, Chordate trained clinic staff and assisted in the initiation of treatment for the first three patients in
At the end of January, we also signed an agreement with a second clinic in
Strong interest at several investing congresses
We participated during the first quarter and thereafter in several international investing congresses that target Life Science, including in
New case report on Ozilia published: “Effective for both pain relief and reduced frequency of migraine attacks”
In March, an Italian case report on Ozilia by a team at Campus BioBedico in
The article also indicates that pain relief and reduction of migraine days from the initial treatment period had a sustained effect. After about three months, the patient underwent another treatment period with Ozilia, resulting in a quicker and more significant response.
Patents approved in
In February, the
The Company thus currently has 79 patents distributed between 32 countries and 9 patent families related to different aspects of the Company's treatment techniques. Each newly granted patent is positive since the Company’s intellectual property rights enable exclusivity on the market, which is a pillar of the ownership value the Company is building.
Strengthened cash after rights issue
The rights issue conducted in
Focus in 2024
- Proof-of-Concept in the focus markets
- Generate attention in the industry and investor circles
- Product registration in
China ,Saudi Arabia ,UAE andUSA
- The studies PM009 and PM010
Kista,
© Modular Finance, source